This will take effect April 14, 2014
Overview and Clinical Utility:
Effective April 14, 2014, PathGroup will change methodologies for the celiac disease panel (tissue transglutaminase and deaminated gliadin IgA and IgG). Methodology will change from enzyme immunoassay to multiplex flow immunoassay.
Click Here to read more.